Phase 1b data shows treatment with SAT-3247 was safe and well-tolerated Pharmacokinetic (PK) profile of SAT-3247 translated as expected to Duchenne Muscular Dystrophy (DMD) patients taking concurrent ...
On Saturday April 5, Anavex announced data from their open-label extension trial, ATTENTION-AD, for early Alzheimer's Disease presented at the AD/PDTM 2025 Conference. ATTENTION-AD is a follow-on ...
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial In this global phase III ...
WAYNE, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory ...
On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals has unveiled two-year biomarker results from an open-label study in those ...
A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer (BR.36). This is an ASCO Meeting Abstract ...
Context Therapeutics announces first patient dosed in Phase 1 trial of CTIM-76 for CLDN6-positive cancers. Initial data expected 2026. Context Therapeutics Inc. has announced the dosing of the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback